Preferred Label : c-Met-targeting Tri-specific Natural Killer Cell Engager ABBV-303;
NCIt synonyms : c-Met-targeting TriNKET ABBV-303; Tri-specific NK Cell Engager ABBV-303; Tri-specific NK Cell Engager Therapeutic Agent ABBV-303;
NCIt definition : An engineered immune modulating agent based on tri-specific natural killer (NK) cell
engager therapy (TriNKET) that is targeting c-Met (hepatocyte growth factor receptor;
HGFR), with potential immunostimulating and antineoplastic activities. Upon administration,
c-Met-targeting tri-specific NK cell engager ABBV-303 targets and binds to c-Met on
tumor cells and simultaneously binds to NK cells via the receptors CD16 and NKG2D
(natural killer group 2D; killer cell lectin-like receptor K1; KLRK1), thereby bringing
c-Met-expressing tumor cells and NK cells together. This activates NK cells and results
in the selective NK cell-mediated killing of c-Met-expressing tumor cells. In addition,
the NK cells activate T- and B-cells, and enhance a cytotoxic T-lymphocyte (CTL)-mediated
immune response against c-Met-expressing tumor cells. C-Met, a receptor tyrosine kinase
that is overexpressed or mutated in many tumor cell types, plays a key role in tumor
cell proliferation, survival, invasion, metastasis, and tumor angiogenesis. Its expression
is associated with poor prognosis in many tumor types.;
Molecule name : ABBV 303; ABBV-303;
NCI Metathesaurus CUI : CL1927409;
Origin ID : C204983;
concept_is_in_subset
- has_target
